PubMedID: 22916186Expansions of the polyglutamine (polyQ) domain (?34) in Ataxin-2 (ATXN2) are the primary cause of spinocerebellar ataxia type 2 (SCA2). Recent studies reported that intermediate-length (27-33) expansions increase the risk of Amyotrophic Lateral Sclerosis (ALS) in 1-4% of cases in diverse populations. This study investigates the Turkish population with respect to ALS risk, genotyping 158 sporadic, 78 familial patients and 420 neurologically healthy controls. We re-assessed the effect of ATXN2 expansions and extended the analysis for the first time to cover the ATXN2 locus with 18 Single Nucleotide Polymorphisms (SNPs) and their haplotypes. In accordance with other studies, our results confirmed that 31-32 polyQ repeats in t...
We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclero...
We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclero...
International audienceThe aim of this study was to establish the frequency of ATXN2 polyglutamine (p...
<div><p>Expansions of the polyglutamine (polyQ) domain (≥34) in Ataxin-2 (ATXN2) are the primary cau...
Expansions of the polyglutamine (polyQ) domain (≥34) in Ataxin-2 (ATXN2) are the primary cause of sp...
Intermediate-length CAG expansions (encoding 27-33 glutamines, polyQ) of the Ataxin2 (ATXN2) gene re...
OBJECTIVE: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in...
To clarify the possible involvement of intermediate ATXN1 alleles as risk factors for amyotrophic la...
Full expansions of the polyglutamine domain (polyQ>/=34) within the polysome-associated protein atax...
TDP-43 is the major disease protein in amyotrophic lateral sclerosis (ALS).1 Recently, ataxin-2, a p...
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease primarily affec...
OBJECTIVE: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with unclear etiology. Rec...
OBJECTIVE: The aim of this study was to establish the frequency of ATXN2 polyglutamine (polyQ) expan...
We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclero...
We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclero...
International audienceThe aim of this study was to establish the frequency of ATXN2 polyglutamine (p...
<div><p>Expansions of the polyglutamine (polyQ) domain (≥34) in Ataxin-2 (ATXN2) are the primary cau...
Expansions of the polyglutamine (polyQ) domain (≥34) in Ataxin-2 (ATXN2) are the primary cause of sp...
Intermediate-length CAG expansions (encoding 27-33 glutamines, polyQ) of the Ataxin2 (ATXN2) gene re...
OBJECTIVE: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in...
To clarify the possible involvement of intermediate ATXN1 alleles as risk factors for amyotrophic la...
Full expansions of the polyglutamine domain (polyQ>/=34) within the polysome-associated protein atax...
TDP-43 is the major disease protein in amyotrophic lateral sclerosis (ALS).1 Recently, ataxin-2, a p...
Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease primarily affec...
OBJECTIVE: Recent evidence suggests that intermediate-length polyglutamine (PolyQ) expansions in the...
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder with unclear etiology. Rec...
OBJECTIVE: The aim of this study was to establish the frequency of ATXN2 polyglutamine (polyQ) expan...
We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclero...
We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclero...
International audienceThe aim of this study was to establish the frequency of ATXN2 polyglutamine (p...